ClinicalTrials.gg
CompletedNCT06291857Updated Jun 5, 2026

A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine

A Phase 3 interventional study of CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant and Novavax COVID-19 Vaccine in COVID-19, sponsored by Novavax. Completed at 58 sites in 2 countries. Open to participants aged 65 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Novavax · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9,320
Allocation
Randomized
Ages
65 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 — none open to participants now, 2 under way, none of them phase 3. NVX-CoV2373 adjuvated lipid nanoparticle · COVID-19.

Enrollment
3rd of 18
9,320 · median 997
Started
2024
with 1 other
Phase 3
7 of 18
none open now
Registered
15th of 18
by date
Lead sponsor
12 of 18
Novavax

Among the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19, this one is the 3rd largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 3, and was the 15th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 is open now. The open studies under COVID-19, anywhere →

About NVX-CoV2373 adjuvated lipid nanoparticle

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 65 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing NVX-CoV2373 adjuvated lipid nanoparticle in COVID-19 as a file.
02

Study summary

This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine. The researchers conducting the study won't know which vaccine each participant receives, ensuring their observations are unbiased. This study compares the new combination vaccine to an already available flu vaccine to see how well it works. It's a large-scale, final-stage study designed to thoroughly check how well the vaccines trigger an immune response (immunogenicity) and how safe they are.

Read the detailed description

The study enrolled a total of 9,320 medically stable (based on history and physical examination) adult male and female participants ≥ 65 years of age across Part 1 and Part 2.

In Part 1, participants were randomly assigned to receive either CIC, Novavax COVID-19 Vaccine, tNIV, or Fluzone High-Dose in a 3:2:1:3 ratio, respectively. Following the completion of enrollment in Part 1, the remaining participants were enrolled into Part 2 and were randomly assigned to receive either CIC, tNIV, or Fluzone High-Dose in a 5:4:1 ratio, respectively.

All participants received a single intramuscular (IM) injection on Day 0.

Part 1: All participants remained on study for immunogenicity data collection through Day 182 and safety data collection through Day 364 (End of Study [EoS]).

Part 2: Only safety was assessed, and all participants remained on study for safety data collection through Day 364 (EoS).

03

Conditions studied

  • COVID-19

Keywords

  • CIC (Coronavirus Disease 2019 Influenza Combination)
  • Influenza
  • Fluzone High-Dose
04

Who can participate

Ages eligible
65 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be included in this study, each individual must satisfy all the following criteria:

  1. Willing and able to give prior to study enrollment.
  2. Medically stable adult male or female ≥ 65 years of age at Screening.
  3. Participants may have 1 or more chronic medical diagnoses, but should be clinically stable as assessed by:

    1. Absence of changes in medical therapy in the past 2 months due to treatment failure or toxicity;
    2. Absence of medical events qualifying as SAEs within 3 months; and
    3. Absence of known, current, and life-limiting diagnoses which render survival to completion of the protocol unlikely in the opinion of the Investigator.
  4. The participant has a (BMI) of 17 to 40 kg/m2, inclusive, at Screening.
  5. Participant must be able to receive an injection in the deltoid of at least 1 arm.
  6. Able to attend study visits, comply with study requirements, and provide reliable and complete reports of AEs.
  7. Participants must have completed a primary vaccination series/booster against SARS CoV-2 with an authorized/approved COVID-19 vaccine, with receipt of last dose of authorized/approved vaccine (with or without boosters[s]) ≥ 8 weeks prior to vaccination.
  8. Female participants must be surgically sterile (ie, have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or (defined as amenorrhea at least 12 consecutive months)
  9. Participants must agree to not participate in any other SARS-CoV-2 or influenza prevention or treatment studies for the duration of the study. Note: For participants who become hospitalized with COVID-19 or influenza, participation in treatment studies is permitted.

Exclusion criteria

Exclusion Criteria

If an individual meets any of the following criteria, he or she is ineligible for this study:

  1. History of laboratory-confirmed (by polymerase chain reaction [PCR], rapid antigen test, or rapid molecular assay) COVID-19, asymptomatic SARS-CoV-2 infection, or influenza within ≤ 8 weeks prior to Screening.
  2. Any ongoing, symptomatic acute illness requiring medical or surgical care or chronic illness that required substantive changes in medication in the past 2 months prior to Screening indicating that chronic illness/disease is not stable (at the discretion of the investigator). This includes any current workup of undiagnosed illness that could lead to a new condition.
  3. Serious chronic diseases inclusive of:

    1. Uncontrolled hypertension (NOTE: hypertension ≤ 170/100 is NOT exclusionary);
    2. Congestive heart failure requiring hospitalization within 3 months prior to Screening
    3. (COPD) requiring hospitalization within 3 months prior to Screening (NOTE: stable COPD is NOT exclusionary);
    4. Within 3 months prior to Screening, evidence of unstable coronary artery disease as manifested by cardiac interventions (eg, cardiac stent placement, coronary artery bypass graft surgery), new cardiac medications for control of symptoms, or unstable angina (NOTE: stable coronary heart disease is NOT exclusionary);
    5. Hospitalization for diabetic ketoacidosis within 6 months prior to Screening
    6. Chronic kidney disease/renal requiring institution of substantive new therapy within 3 months prior to Screening
    7. Chronic gastrointestinal and hepatic diseases requiring hospitalization or institution of substantive new therapy within 3 months prior to Screening. (for example, gastroesophageal reflux disease is NOT exclusionary)
    8. Chronic neurological diseases or neurological compromise preventing access to the study clinic, compliance with protocol, or accurate reporting of safety.
  4. Participation in research involving an product (drug/biologic/device) within 90 days before planned date of vaccination.
  5. Use of COVID-19 prophylactic or treatment monoclonal antibodies or antibody cocktails within 90 days prior to planned date of vaccination.
  6. History of a serious reaction to a prior influenza vaccination or known allergy to constituents of influenza vaccines - including egg proteins - or polysorbate 80; or any known allergies to products contained in the investigational product.
  7. Any history of anaphylaxis to any prior vaccine.
  8. History of Guillain-Barré Syndrome following a previous influenza vaccine.
  9. Receipt of any vaccine in the 4 weeks preceding the study vaccination and any influenza vaccine within 2 months preceding the study vaccination. Note: Routine vaccinations will not be allowed until after study Day 21 and COVID-19 and influenza vaccination will not be allowed until after Day 84.
  10. Any known or suspected or illness, congenital or acquired, based on medical history and/or physical examination (NOTE: well-controlled hypothyroidism and mild psoriasis are not exclusionary).
  11. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccines. An immunosuppressant dose of is defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids is permitted.
  12. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
  13. Active cancer () therapy within 1 year prior to study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma or lentigo maligna and uterine cervical carcinoma in situ without evidence of disease, at the discretion of the investigator).
  14. Participants who are breastfeeding, pregnant, or who plan to become pregnant prior to the EoS.
  15. Suspected or known history of alcohol abuse or drug addiction within 2 years prior to study vaccination, which in the opinion of the investigator, might interfere with protocol compliance.
  16. Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature ≥ 38.0°C, on the planned day of vaccine administration).
  17. History of myocarditis or pericarditis.
  18. Any condition that in the opinion of the investigator would pose a health risk to the participant if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
  19. Study team member or immediate family member of any study team member (inclusive of Sponsor, Contract Research Organization, and study site personnel involved in the conduct or planning of the study).
  20. Known history of any prior motor neuropathy.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
9,320 participants (actual)

Study arms

  • Experimental
    CIC Vaccine

    A single 0.5 mL IM injection on Day 0

    Biological: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant

  • Experimental
    Novavax COVID-19 Vaccine

    A single 0.5 mL IM injection on Day 0

    Biological: Novavax COVID-19 Vaccine

  • Experimental
    tNIV Vaccine

    A single 0.5 mL IM injection on Day 0

    Biological: tNIV Vaccine

  • Experimental
    Fluzone High-Dose

    A single 0.5 mL IM injection on Day 0

    Biological: Fluzone High Dose

Interventions

  • BiologicalCIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant

    CIC will contain SARs-CoV-2 antigen (35 μg), tNIV antigens (2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains; 60 μg/strain

    Also known as: COVID-19 and influenza combination

  • Each 0.5 mL dose comprises 5 µg SARS-CoV-2 S protein and 50 µg Matrix-M adjuvant

    Also known as: Novavax SARS-CoV-2 rS vaccine

  • BiologicaltNIV Vaccine

    2 influenza A \[H1N1 and H3N2\] and 1 influenza B-Victoria lineage strains (60 μg/strain), and Matrix-M adjuvant (75 μg)

    Also known as: Trivalent Nanoparticle Influenza Hemagglutinin Vaccine

  • BiologicalFluzone High Dose

    Fluzone High-Dose is supplied as a suspension for IM injection 0.5 mL with 60 µg per strain

    Also known as: Fluzone HD

06

What researchers measure

Primary outcomes

  1. Numbers of participants with solicited local and systemic adverse events (AEs)

    Numbers of participants with solicited local and systemic AEs over the 7 days post-vaccination.

    Time frame: Day 7

  2. Numbers of participants reporting unsolicited AEs and medically attended adverse events (MAAEs).

    Numbers of participants reporting unsolicited AEs and MAAEs over 21 days post-vaccination.

    Time frame: Day 28

  3. Treatment-related MAAEs, serious adverse events (SAEs), and adverse events of special interest (AESIs) (including potential immune-mediated medical conditions [PIMMCs] and myocarditis and/or pericarditis)

    Numbers of participants with treatment-related MAAEs, AESIs (including PIMMC and myocarditis and/or pericarditis), and SAEs will be collected for 12 months (approximately 364 days) post-vaccination.

    Time frame: Day 0 to Day 364

  4. Hemagglutination Inhibition (HAI) antibody responses of the CIC vaccine compared to Fluzone High-Dose of homologous A and B strains Expressed as GMT

    Hemagglutination Inhibition (HAI) antibody responses of the CIC vaccine compared to Fluzone High-Dose of homologous influenza strains (two influenza A strains and one influenza B-Victoria lineage strain) on Days 0 and 28

    Time frame: Days 0 and 28

  5. Hemagglutination Inhibition (HAI) antibody responses of the CIC vaccine compared to Fluzone High-Dose of homologous A and B strains Expressed as GMTR

    Hemagglutination Inhibition (HAI) antibody responses of the CIC vaccine compared to Fluzone High-Dose of homologous influenza strains (two influenza A strains and one influenza B-Victoria lineage strain) on Days 28

    Time frame: Day 28

  6. Percentage of Participants With a (HAI) antibody responses of the CIC vaccine compared to Fluzone High-Dose for 3 vaccine-homologous influenza strains Expressed as SCR

    Percentage of Participants With a (HAI) antibody responses of the CIC vaccine compared to Fluzone High-Dose for 3 vaccine-homologous influenza strain on Days 28

    Time frame: Day 28

  7. Neutralizing Antibody (NAb) Responses of the CIC vaccine compared to Fluzone High-Dose of homologous A and B strains Expressed as GMT

    Neutralizing Antibody (NAb) Responses Assessed against three homologous influenza strains (two influenza A strains and one influenza B-Victoria lineage strain) on Day 28

    Time frame: Day 28

  8. Neutralizing Antibody (NAb) Responses of the CIC vaccine compared to Fluzone High-Dose of homologous A and B strains Expressed as GMTR

    Neutralizing Antibody (NAb) Responses Assessed against three homologous influenza strains (two influenza A strains and one influenza B-Victoria lineage strain) on Day 28

    Time frame: Day 28

  9. Percentage of Participants With a (NAb) Responses of the CIC vaccine compared to Fluzone High-Dose of homologous A and B strains Expressed as SCR

    Neutralizing Antibody (NAb) Responses Assessed against three homologous influenza strains (two influenza A strains and one influenza B-Victoria lineage strain) on Day 28

    Time frame: Day 28

  10. Hemagglutination Inhibition (HAI) antibody titers specific to HA receptor-binding domains of (tNIV) comparable to Fluzone High-Dose of homologous influenza A and B strains expressed as GMT

    Hemagglutination Inhibition (HAI) antibody titers specific to HA receptor-binding domains of (tNIV) comparable to Fluzone High-Dose of 2 influenza A strains and an influenza B-Victoria lineage strain) on Day 28

    Time frame: Day 28

  11. Hemagglutination Inhibition (HAI) antibody titers specific to HA receptor-binding domains of (tNIV) comparable to Fluzone High-Dose of homologous influenza A and B strains expressed as GMTR

    Hemagglutination Inhibition (HAI) antibody titers specific to HA receptor-binding domains of (tNIV) comparable to Fluzone High-Dose of 2 influenza A strains and an influenza B-Victoria lineage strain) on Day 28

    Time frame: Day 28

  12. Percentage of Participants with (HAI) antibody titers specific to HA receptor-binding domains of (tNIV) comparable to Fluzone High-Dose of homologous influenza A and B strains expressed as SCR

    Hemagglutination Inhibition (HAI) antibody titers specific to HA receptor-binding domains of (tNIV) comparable to Fluzone High-Dose of 2 influenza A strains and an influenza B-Victoria lineage strain) on Day 28

    Time frame: Day 28

Secondary outcomes

  1. Immunogenicity- HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B influenza strains Expressed as Geometric Mean Titers (GMT)

    HAI antibody titers specific for the HA receptor binding domains of vaccine response CIC vaccine compared to Fluzone High-Dose on Day 28

    Time frame: Day 28

  2. Immunogenicity- HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B influenza strains Expressed as GMFR

    HAI antibody titers specific for the HA receptor binding domains of vaccine response CIC vaccine compared to Fluzone High-Dose on Day 28

    Time frame: Day 28

  3. Percentage of Participants with HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B influenza strains Expressed as SCR

    HAI antibody titers specific for the HA receptor binding domains of vaccine response CIC vaccine compared to Fluzone High-Dose on Day 28

    Time frame: Day 28

  4. HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B influenza strains Expressed as GMTR

    HAI antibody titers specific for the HA receptor binding domains of vaccine response CIC vaccine compared to Fluzone High-Dose on Day 28

    Time frame: Day 28

  5. Influenza NAb responses: neutralizing antibody titers specific to vaccine homologous wild-type A and B influenza strains, is expressed as GMT

    Neutralizing antibody titers specific to vaccine homologous influenza strains (ie, 2 influenza A strains and an influenza B-Victoria lineage strain) as measured by a neutralization assay, CIC and Fluzone High Dose on Day 28

    Time frame: Day 28

  6. Influenza NAb responses: neutralizing antibody titers specific to vaccine homologous wild-type A and B influenza strains, is expressed as GMFR

    Neutralizing antibody titers specific to vaccine homologous influenza strains (ie, 2 influenza A strains and an influenza B-Victoria lineage strain) as measured by a neutralization assay, CIC and Fluzone High Dose on Day 28

    Time frame: Day 28

  7. Percentage of Participants with a NAb responses: neutralizing antibody titers specific to vaccine homologous wild-type A and B influenza strains, is expressed as SCR

    Neutralizing antibody titers specific to vaccine homologous influenza strains (ie, 2 influenza A strains and an influenza B-Victoria lineage strain) as measured by a neutralization assay, CIC and Fluzone High Dose on Day 28

    Time frame: Day 28

  8. Influenza NAb responses: neutralizing antibody titers specific to vaccine homologous wild-type A and B influenza strains, is expressed as GMTR

    Neutralizing antibody titers specific to vaccine homologous influenza strains (ie, 2 influenza A strains and an influenza B-Victoria lineage strain) as measured by a neutralization assay, CIC and Fluzone High Dose on Day 28

    Time frame: Day 28

  9. Hemagglutination Inhibition (HAI) antibody titers to tNIV and Fluzone High-Dose Expressed as GMT

    Hemagglutination Inhibition (HAI) antibody titers specific to HA receptor-binding domains of vaccine-homologous influenza A and B strains on Day 28

    Time frame: Day 28

  10. Hemagglutination Inhibition (HAI) antibody titers to tNIV and Fluzone High-Dose Expressed as GMFR

    Hemagglutination Inhibition (HAI) antibody titers specific to HA receptor-binding domains of vaccine-homologous influenza A and B strains on Day 28 homologous SARS-CoV-2 strain CIC, Fluarix or Fluzone HD, and Novavax COVID-19 Vaccine expressed as SCR

    Time frame: Day 28

  11. Percentage of Participants with (HAI) antibody titers to tNIV and Fluzone High-Dose Expressed as SCR

    Hemagglutination Inhibition (HAI) antibody titers specific to HA receptor-binding domains of vaccine-homologous influenza A and B strains on Day 28

    Time frame: Day 28

  12. Influenza neutralizing antibody (NAb) responses of trivalent nanoparticle influenza vaccine (tNIV) comparable to Fluzone High-Dose Expressed as GMT

    Influenza neutralizing antibody (NAb) responses of trivalent nanoparticle influenza vaccine (tNIV) comparable to Fluzone High-Dose against three influenza strains (two A strains and one B-Victoria strain) on Day 28.

    Time frame: Day 28

  13. Influenza neutralizing antibody (NAb) responses of trivalent nanoparticle influenza vaccine (tNIV) comparable to Fluzone High-Dose Expressed as GMFR

    Influenza neutralizing antibody (NAb) responses of trivalent nanoparticle influenza vaccine (tNIV) comparable to Fluzone High-Dose against three influenza strains (two A strains and one B-Victoria strain) on Day 28.

    Time frame: Day 28

  14. Influenza neutralizing antibody (NAb) responses of trivalent nanoparticle influenza vaccine (tNIV) comparable to Fluzone High-Dose Expressed as GMTR

    Influenza neutralizing antibody (NAb) responses of trivalent nanoparticle influenza vaccine (tNIV) comparable to Fluzone High-Dose against three influenza strains (two A strains and one B-Victoria strain) on Day 28.

    Time frame: Day 28

  15. Percentage of Participants with (NAb) responses of trivalent nanoparticle influenza vaccine (tNIV) comparable to Fluzone High-Dose Expressed as SCR

    Influenza neutralizing antibody (NAb) responses of trivalent nanoparticle influenza vaccine (tNIV) comparable to Fluzone High-Dose against three influenza strains (two A strains and one B-Victoria strain) on Day 28.

    Time frame: Day 28

07

Study locations

58 sites
  • Paratus Clinical Research - Canberra - PPDS
    Bruce, Australian Capital Territory 2617, Australia
  • Momentum Wellers
    Wellers Hill, Brisbane 4121, Australia
  • Paratus Clinical Research - Western Sydney - PPDS
    Blacktown, New South Wales 2148, Australia
  • Key Health- Bondi Junction
    Bondi Junction, New South Wales 2022, Australia
  • Emeritus Research - Sydney - PPDS
    Botany, New South Wales 2019, Australia
  • Genesis Research Services
    Broadmeadow, New South Wales 2292, Australia
  • Northern Beaches Clinical Research - PPDS
    Brookvale, New South Wales 2100, Australia
  • Northside Health
    Coffs Harbour, New South Wales 2450, Australia
  • East Sydney Doctors
    Darlinghurst, New South Wales 2010, Australia
  • Momentum Darlinghurst
    Darlinghurst, New South Wales 2010, Australia
  • Oztrials Clinical Research
    Drummoyne, New South Wales 2047, Australia
  • Paratus Clinical Research - Central Coast - PPDS
    Kanwal, New South Wales 2259, Australia
  • Novatrials
    Kotara, New South Wales 2289, Australia
  • Australian Clinical Research Network
    Maroubra, New South Wales 2035, Australia
  • Hunter Diabetes Centre
    Merewether, New South Wales 2291, Australia
  • Sutherland Shire Clinical Research - PPDS
    Miranda, New South Wales 2228, Australia
  • Pioneer Clinical Research - North Sydney
    North Sydney, New South Wales 2060, Australia
  • Taylor Square Private Clinic
    Surry Hills, New South Wales 2010, Australia
  • Momentum St Leonards
    Sydney, New South Wales 2065, Australia
  • Innovate Clinical Research Pty Ltd
    Sydney, New South Wales 2077, Australia
  • Wollongong Clinical Research - PPDS
    Wollongong, New South Wales 2500, Australia
  • Menzies School of Health Research
    Casuarina, Northern Territory 0810, Australia
  • University of the Sunshine Coast, Vitality Village - UniSC Clinical Trials - PPDS
    Birtinya, Queensland 4575, Australia
  • Momentum Taringa
    Brisbane, Queensland 4068, Australia
  • Griffith University Clinical Trials Unit
    Griffith, Queensland 4222, Australia
  • Nucleus Network Pty Ltd
    Herston, Queensland 4006, Australia
  • Paratus Clinical Research - Brisbane Clinic - PPDS
    Herston, Queensland 4006, Australia
  • Mater Hospital Brisbane
    South Brisbane, Queensland 4101, Australia
  • Cmax - Ppds
    Adelaide, South Australia 5000, Australia
  • Veritus Research - Emeritus - PPDS
    Bayswater, Victoria 3153, Australia
  • Emeritus Research -PPDS
    Camberwell, Victoria 3124, Australia
  • Ryrie St, Geelong, VIC 3220, Australia
    Geelong, Victoria 3220, Australia
  • Doherty Clinical Trials Limited
    Melbourne, Victoria 3000, Australia
  • Nucleus Network Limited
    Melbourne, Victoria 3004, Australia
  • Momentum Sunshine
    Melbourne, Victoria 3021, Australia
  • University of Melbourne - Melbourne
    Melbourne N., Victoria 3051, Australia
  • Institute for Respiratory Health - Midland
    Midland, Western Australia 6056, Australia
  • Telethon Kids Institute
    Nedlands, Western Australia 6009, Australia
  • CliniTrials
    Perth, Western Australia 6000, Australia
  • Momentum Tauranga - PPDS
    Tauranga, Bay of Plenty 3110, New Zealand
  • Momentum Hawke's Bay - PPDS
    Hastings, Hawke's Bay Region 4122, New Zealand
  • Momentum Dunedin - PPDS
    Dunedin, Otago 9016, New Zealand
  • Southern Clinical Trials - Totara - PCRN - PPDS
    Auckland, 0600, New Zealand
  • Pacific Clinical Research Network - Auckland - PCRN - PPDS
    Auckland, 0622, New Zealand
  • Optimal Clinical Trials Ltd - North Shore - PPDS
    Auckland, 0632, New Zealand
  • Optimal Clinical Trials Ltd - PPDS
    Auckland, 1010, New Zealand
  • Momentum Pukekohe - PPDS
    Auckland, 2120, New Zealand
  • New Zealand Clinical Research - Christchurch - PPDS
    Christchurch, 8011, New Zealand
  • Pacific Clinical Research Network - Christchurch - PCRN - PPDS
    Christchurch, 8013, New Zealand
  • Lakeland Clinical Trials - Waikato - PCRN-PPDS
    Hamilton, 3243, New Zealand
  • Momentum Lower Hutt - PPDS
    Lower Hutt, New Zealand
  • Southern Clinical Trials - Tasman - PCRN - PPDS
    Nelson, 7011, New Zealand
  • Momentum Palmerston North - PPDS
    Palmerston North, 4414, New Zealand
  • Pacific Clinic Research Network - Rotorua - PCRN - PPDS
    Rotorua, 3010, New Zealand
  • Momentum Kapiti - PPDS
    Waikanae, 5036, New Zealand
  • Lakeland Clinical Trials - Wellington - PCRN - PPDS
    Wellington, 5018, New Zealand
  • Momentum Wellington - PPDS
    Wellington, 6021, New Zealand
  • Aotearoa Clinical Trials Trust
    Wellington, New Zealand
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Dec 2025, 12 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 12 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2024
First posted
Mar 4, 2024
StartActual
Dec 9, 2024
Primary completionActual
Dec 24, 2025
CompletionActual
Feb 9, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06291857
Lead sponsor
Novavax
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Dec 9, 2024
Primary completion
Dec 24, 2025
Completion
Feb 9, 2026
Last update
Jun 5, 2026

Study contacts

Clinical Development
study director · Novavax, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: NVX-CoV2373 adjuvated lipid nanoparticle

Start the discussion